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Abstract
Background: Postoperative chemoradiation as per Intergroup-0116 trial (“Macdonald regimen”) is considered
standard for completely resected high risk gastric cancer. However, many concerns remain with regards to the
toxicity of this regimen. To evaluate the safety and tolerability of this regimen in a routine clinical practice setting,
we analyzed our experience with its use. As we did not expect a different toxic profile in patients (pts) with
positive margins (R1 resection), these were studied together with pts after complete resection (R0).
Patients and Methods: Postoperative chemoradiation therapy was given according to the original Intergroup-
0116 regimen. Overall survival (OS) and disease free survival (DFS) rates were calculated using the Kaplan-Meier
method. Comparison of OS and DFS between R0 and R1 pts was done using the log-rank test.
Results: Between 6/2000 and 12/2007, 166 pts after R0 (129 pts) or R1 (37 pts) resection of locally advanced
gastric adenocarcinoma received postoperative chemoradiation; 61% were male and the median age was 63 years
(range, 23-86); 78% had T ≥ 3 tumors and 81% had N+ disease; 87% of the pts completed radiotherapy and 54%
completed the entire chemoradiation plan; 46.4% had grade ≥ 3 toxicity and 32% were hospitalized at least once
for toxicity. Three pts (1.8%) died of toxicity: diarrhea (1), neutropenic sepsis (1) and neutropenic sepsis complicated
by small bowel gangrene (1). The most common hematological toxicity was neutropenia, grade ≥ 3 in 30% of pts
and complicated by fever in 15%. The most common non-hematological toxicities were nausea, vomiting and
diarrhea. With a median follow-up of 51 months (range, 2-100), 62% of the R0 patients remain alive and 61% are
free of disease. Median DFS and OS for R0 were not reached. R0 pts had a significantly higher 3-year DFS (60% vs.
29%, p = 0.001) and OS (61% vs. 33%, p = 0.01) compared with R1 pts.
Conclusions: In our experience, postoperative chemoradiation as per Intergroup-0116 seems to be substantially toxic,
with a mortality rate which seems higher than reported in that trial. Efficacy data appears comparable to the original
report. Following postoperative chemoradiation, involvement of surgical margins still has a detrimental impact on
patient outcome.
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Gastric cancer is the second leading cause of cancer
related death among men and the fourth among women,
and thus represents a significant global health concern
[1]. The disease is commonly diagnosed at an advanced
stage, either with extensive locoregional involvement or
with overt distant metastases. Overall 5-year survival rate
approximates 20% and has undergone minimal change
over the last decade [1].
Complete surgical resection of gastric cancer is curative
in less than 40% of cases [2]. In patients with deep inva-
sion of the gastric wall or regional lymph node metas-
tases the relapse and death rates from recurrent cancer
exceed 70-80%. Loco-regional recurrences in the tumor
bed, the anastomosis or in regional lymph nodes occur in
40 to 65% of patients after curative intent resection [3];
the frequency of this relapse makes regional radiotherapy
an attractive possibility for adjuvant therapy.
Most previous adjuvant trials have failed to demonstrate
significant survival advantage in gastric cancer. U.S. Inter-
group study (INT-0116) was the first to demonstrate that
combined chemoradiation following complete gastric
resection improves median relapse-free survival (30 vs. 19
months, p < 0.0001) and overall survival (OS) (36 vs. 27
months, p = 0.01) [4]. The 3-year survival rates were 41%
and 50%, respectively (p = 0.005). Following these results,
postoperative adjuvant chemoradiation as per the INT-
0116 trial, the so-called “Macdonald regimen”, became the
new standard of care. However, much concern remains
regarding the toxicity of the regimen. Forty-one percent of
patients in INT-0116 had grade 3 toxicity and 32% had
grade 4 toxicity. Three patients (1%) suffered toxic deaths
and 31% did not complete treatment due to toxicity.
The aim of this retrospective multi-institutional study
was to evaluate the safety and tolerability of the INT-0116
regimen outside the frame of a clinical trial, in a routine
clinical practice setting in Israel.
Patients and Methods
Patients
The study population consisted of all consecutive patients
who were treated by the INT-0116 regimen in one of the
participating centers, after the adoption of this regimen as
the standard of care, and who fulfilled the study’se l i g i b i l i t y
criteria. Patients were required to have histologically con-
firmed adenocarcinoma of the stomach, with macroscopic
complete resection of the tumor, disease stage IB to IV
(M0) according to the 1997 staging criteria of the Ameri-
can Joint Commission on Cancer [5], an Eastern Coopera-
tive Oncology Group performance status (PS) of ≤ 2,
adequate organ function (including cardiac, hepatic and
renal functions), adequate bone marrow function (hemo-
globin ≥ 10 g/dl; leukocyte count ≥ 4,000/μl; platelet count
≥ 100,000/μl) and an oral caloric intake ≥ 1,500 kcal per
day. All patients underwent chest radiographs and abdo-
minopelvic computed tomography to exclude distant
metastases.
Surgery
The surgical requirements for eligibility were surgery
with curative intent and en bloc resection of the tumor
with macroscopically negative margins. As the primary
endpoint of the study was safety and we did not expect a
difference in that endpoint between patients with micro-
scopic positive margins (R1 resection) and those who
underwent complete resection (R0), both groups were
included. Eighty-five percent of the patients underwent
D0 lymph node dissection and the remaining 15% under-
went D1 dissection.
Chemoradiotherapy
The regimen of fluorouracil (5-FU) and leucovorin (LV)
was given according to the INT-0116 trial. Chemotherapy
with 5-FU 425 mg/m
2/day and LV 20 mg/m
2/day was
administered on days 1-5 and was followed by chemora-
diotherapy 4 weeks after the start of the initial cycle of
chemotherapy. Chemoradiotherapy consisted of 45 Gy of
radiation at 1.8 Gy/day, 5 days/week for 5 weeks, with a
reduced dose of 5-FU (400 mg/m
2)p l u sL Vo nt h ef i r s t
4 and the last 3 days of radiation. Four weeks after the
completion of radiotherapy, two five-day cycles of 5-FU
(425 mg/m
2) and LV were given 4 weeks apart. Radiother-
apy was delivered to the tumor bed, as defined by preo-
perative imaging, the regional lymph nodes, and 2 cm
beyond the proximal and distal margins of resection. The
dose was prescribed to the isodose line encompassing 95%
of the planning tumor volume (PTV).
Patient evaluation
Patients were followed at 3-month intervals for 2 years, at
6-month intervals for the next 3 years and yearly there-
after. Follow-up consisted of physical examination, com-
plete blood count and liver function tests. Imaging studies
and gastroscopy were done when clinically indicated. The
site of relapse was classified as follows: locoregional if the
tumor was detected within the radiation field (including
surgical anastomosis, remnant stomach or gastric bed);
peritoneal if the tumor was detected in the peritoneal cav-
ity; and distant in case of liver metastasis or metastases
outside the peritoneal cavity.
Statistical analysis
OS was defined as the time from surgery to death or the
last date the patient was known to be alive. Disease-free
survival (DFS) was defined as the time from surgery to
recurrence of cancer or to the last date the patient was
known to be disease-free. The Kaplan-Meier product-
limit method [6] was used to estimate survival rates.
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was performed using the log-rank test. The study was
approved by the institutional ethics committee.
Results
Patient characteristics
Between 6/2000 and 12/2007, 166 patients with locally
advanced gastric cancer received post-operative chemora-
diation as per INT-0116 at the participating centers. The
patients’ characteristics are shown in Table 1. The median
age was 63 years (range, 23-86) and the majority (60%)
were males. Tumor location was equally distributed in the
stomach. Most of the patients had advanced localized dis-
ease: 77% had T3-4 tumors and 85% had lymph node
involvement.
Treatment
As shown in Table 1, all patients underwent gastrectomy
with curative intent, 129 (78%) with R0 resection and 37
(22%) with R1 resection. In total, 57% completed the che-
motherapy, 87% completed the radiotherapy and 54%
completed the entire chemoradiotherapy protocol. The
reason for discontinuation was toxicity in all cases.
Toxicity
Overall, 46.4% of the patients experienced grade ≥ 3 toxi-
city. Hematological toxicity of any grade was seen in 51%
and non-hematological toxicity of any grade was experi-
enced by 90%. The most common severe hematological
toxicities were neutropenia and leukopenia (grade ≥ 3i n
30% and 25% of patients, respectively), with 15% of the
patients experiencing at least one episode of neutropenic
fever (Table 2). The most common severe non-hematolo-
gical toxicities were nausea, vomiting and diarrhea, with
approximately 10% of the patients experiencing grade ≥ 3
of each of these side effects (Table 3). Three patients
(1.8%) died due to treatment-related toxicity: one patient
died from sepsis, one from diarrhea and one from neu-
tropenic sepsis complicated with small bowel gangrene.
Forty-eight patients (29%) were hospitalized for toxicity.
Survival and relapse
The median follow-up for the entire group was 51 months
(range, 2-112). At a median follow-up of 51 months
Table 1 Patient Characteristics at the start of
postoperative treatment
Number of patients (%)
Age, yrs
Median (range) 63 (23-86)
Gender
Male 100 (60)
Female 66 (40)
R status
R0 129 (78)
R1 37 (22)
Grade
I-II 32 (19)
III-IV 129 (78)
Unknown 5 (3)
Location
Proximal 48 (29)
Body 55 (33)
Distal 60 (36)
Unknown 3 (2)
T Stage
T1-T2 39 (23)
T3-T4 127 (77)
Lymph node status
N0 25 (15)
N1 80 (48)
N2 37 (22)
N3 24 (15)
Table 2 Hematological toxicity of postoperative
chemoradiation
Median Nadir
(/mm
3)(range)
% of patients
Grade ≥ 3 All grades
Any 32 51
WBC 3,200
(180-10, 280)
25 45
ANC 1,700
(0-7, 800)
30 43
Neutropenic fever -1 5 -
PLT 152,500
(11,000-344,000)
34
WBC = white blood cells, ANC = absolute neutrophil count, PLT = platelets.
Table 3 Non-hematological toxicities of postoperative
chemoradiation
Type of toxic effect % of patients
Grade ≥ 3 All grades
Any 25.3 90
Nausea 10 65
Vomiting 94 0
Diarrhea 10 35
Stomatitis 73 4
Anorexia 54 4
Abdominal pain 43 3
Esophagitis
1 41 9
Fatigue 63 4
Dermatological 06
Hepatic 02
Radiation pneumonitis 01
1Including 2 patients with documented Cytomegalous virus (CMV) esophagitis.
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died of gastric cancer, 61% are alive without evidence of
disease and 1% are alive with recurrent disease. Sixty per-
cent of the relapses occurred at distant sites, 22% of them
were locoregional and 18% were combined. The estimated
3-year DFS and OS of the R0 patients were 60% and 61%,
respectively. The median DFS and OS of these patients
have not been reached. With a median follow-up of
51 months (range, 6-112) for the 37 R1 patients, 59% died
of gastric cancer, 30% are alive without evidence of recur-
rence and 11% are alive with disease. Seventy percent of
the relapses in this group occurred at distant sites, 15%
were locoregional and 15% were combined. The estimated
3-year DFS and OS of the R1 patients were 29% and 33%,
respectively. The median DFS in this group was 15
months and the median OS was 22 months. The DFS (p =
0.001) and OS (p = 0.01) were significantly longer in the
R0 group compared with the R1 group (Figures 1 and 2).
In contrast, there was no difference in outcome between
patients who underwent D0 lymph node dissection (85%
of patients) and those who underwent D1 dissection (15%)
(data not shown).
Discussion
Adjuvant chemoradiotherapy became a standard treat-
ment option for locally advanced gastric cancer after the
publication of the results of the INT-0116 trial that
demonstrated OS advantage with this strategy [4]. How-
ever, this study is still associated with many open ques-
tions and concerns. A key obstacle to the adoption of the
chemoradiation used in INT-0116 is the significant toxi-
city reported for this regimen, including treatment-
related deaths. This is of greater concern when such a
reportedly toxic regimen is to be administered outside
the relatively secured framework of a clinical trial and to
be adopted into the routine practice. This multi-institu-
tional Israeli retrospective study was done in this per-
spective, in order to evaluate the actual performance of
the INT-0116 regimen, the so-called “Macdonald regi-
men”, in common daily practice. While the INT-0116
Figure 1 Disease-free survival by surgical margins.
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the original publication, its results have not been
reported before.
A comparison of the main patient and tumor charac-
teristics as well as treatment results, in terms of toxicity
and efficacy, between the INT-0116 trial and the current
study, is depicted in Table 4. The patient populations in
both studies were very similar, with a median age in the
early 60s and a small male predominance. In both studies
most tumors were classified as T3-4 and/or N+ although
in the current one there was slightly higher proportion of
T3-4 tumors (77% vs. 68%). The toxicity pattern was also
very similar, with most toxicities being hematological or
gastrointestinal and with comparable rates of severe
(grade ≥ 3) toxicities and toxicity-related treatment dis-
c o n t i n u a t i o n s .T h er a t eo fh o s p i t a l i z a t i o n sw a sn o t
reported in INT-0116 and was relatively high (32%) in
our study. With small absolute numbers in both studies,
t h er a t eo ft o x i cd e a t h si nt h ec u r r e n ts t u d yw a sa l m o s t
double than in INT-0116 (1.8% vs. 1.0%). To compare
the efficacy of chemoradiation in both studies, the DFS
and OS rates of the R0 patients in our study were
matched with those of the INT-0116 population. We
found that the outcome of our patients was at least as
good as that of the patients in INT-0116.
The current study largely confirms the toxicity and effi-
cacy reported in INT-0116. However, several issues seem
to deserve attention. First, our higher rate of fatal toxicities
is in accordance with the high rate of hospitalizations that
we observed, a figure not provided in INT-0116. It is possi-
ble that these findings are the result of a less tight monitor-
ing in the common daily practice, but they re-emphasize
the toxicity of the regimen and the concerns regarding its
place outside a clinical trial framework. Second, the survi-
v a lr a t e si no u rs t u d ym a yb es l i g h t l yh i g h e rt h a nt h o s e
reported in INT-0116, while our patients had at least as
advanced tumors as those in that study. It is unclear
whether these are coincidental non-significant differences
or whether they actually reflect the improvement in radio-
therapy techniques and chemotherapy supportive measures
since the original study. Moreover, cross-study comparison
is problematic since no randomization or control of poten-
tial confounders are feasible. Finally, in both studies the
majority of the relapses were distant. This is probably due
to the dissimilar effectiveness of the radiotherapy and the
chemotherapy used in INT-0116.
Figure 2 Overall survival by surgical margins.
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the decade that elapsed since its original publication,
multiple other studies were reported on postoperative
chemoradiation of gastric cancer. The main features of
several representative examples and the INT-0116 study
are summarized in Table 5 [4,7-22].
Altogether, it is difficult to compare the results of INT-
0116 with the other studies, as their data are limited and
very heterogeneous, for several reasons. First, with the
exception of a single phase III study, by Di Costanzo et al.
[7], and a single randomized phase II trial, by Oechsle
et al. [8], all studies were phase I or II trials or, more com-
monly, retrospective analyses. Secondly, aside of the ran-
domized studies described, the retrospective analysis by
K i me ta l .[ 9 ]a n dt h ec u r r e n ts t u d y ,a l lo t h e rs t u d i e s
included only a few dozens of patients each. Thirdly, there
was a large variability of the chemoradiation protocol
used, including both the chemotherapy regimen and the
radiotherapy technique. Lastly, there was significant incon-
sistency in the endpoints reported, regarding both toxicity
and efficacy. Still, review of these studies seems to support
the initial perspective of the INT-0116 results, including
the appreciation of the toxicity of this treatment as well as
its benefit.
To date, the only randomized phase III study to include
the INT-0116 regimen is the CALGB 80101 trial. In this
trial, patients were randomized to receive the original
INT-0116 5FU/LV regimen or ECF (epirubicin/cisplatin/
5FU). The chemoradiation regimen was identical in both
arms, with continuous infusion of 5FU replacing the
bolus 5FU/LV of INT-0116. According to the final results
of the study, which have just been reported, ECF is asso-
ciated with a lower rate of severe toxicities but not with a
superior efficacy [10]. Undoubtedly, in light of the toxi-
city of the INT-0116 regimen and its limited activity,
there is an urgent need to improve each one of its com-
ponents as well as their mode of co-administration. In
terms of efficacy, the “Achilles heel” of this regimen is
clearly its chemotherapy component. This is evident by
the high rate of distant metastases among treated
patients. One possible way to improve the efficacy of
INT-0116 chemotherapy is to integrate newer che-
motherapy agents, such as the taxanes, oxaliplatin and
oral fluoropyrimidines, in the treatment. Another pro-
mising way is to combine chemotherapy with biological
agents. One such potential agent is trastuzumab, which
has been shown to improve substantially the results of
chemotherapy in advanced gastric cancer with over-
expression of HER2 [11]. A different approach to
enhance the efficacy of INT-0116 chemotherapy is to
modify the timing of its delivery. Perioperative adminis-
tration of chemotherapy, like in the MAGIC trial [12], is
one example for such approach.
As the primary objective of our study was to evaluate
the safety of the INT-0116 regimen in daily practice, it
included also 37 patients who had microscopic positive
(R1) margins. In the absence of clear guidelines on the
treatment of such patients, they were given the benefit of
doubt that an “adjuvant” treatment might cure their dis-
ease or at least postpone its relapse. The effectiveness of
this treatment seemed to be limited, as most patients
relapsed early, frequently with overt distant spread.
Nonetheless, our results seem to imply at least some ben-
efit for the postoperative treatment, as nearly 30% of the
R1 patients in our study remained free of recurrence at
three years from surgery. Review of the literature reveals
very limited data on this relatively common condition. In
fact, to our knowledge, our series is by far larger than any
of the five previously reported series on patients under-
going R1 gastrectomies [13-17]. In all other series too,
except one in which postoperative treatment consisted of
the combination of capecitabine and oxaliplatin [16], the
INT-0116 regimen was used as adjuvant treatment
[13-15,17]. Interestingly, in spite of the very small num-
bers, all series seem to indicate a similar outcome follow-
ing R1 resection, with approximately one third of the
patients enjoying protracted remissions. The benefit of
postoperative chemoradiation in these patients is also
suggested by the fact that more than half the patients in
our study and others remained free of local recurrence,
an unusual figure in the presence of involved margins
Table 4 Comparison between the current study and
Intergroup-0116
Current study INT-0116
Patient population
Median age, yrs 63 60
Male, % 60 72
T3-T4, % 77 68
N+, % 85 85
Toxicity
Most common toxicities Hem. + GI Hem. + GI
Grade 3 toxicity 35% 41%
Grade 4 toxicity 22% 32%
Hospitalizations 32% NA
Toxic deaths 1.8% 1%
Discontinuation due to toxicity 36% 31%
efficacy
1
3-year-DFS 60% 48%
3-year-OS 61% 50%
Proportion of distant relapses
2 60% 65%
Hem. = hematological, GI = gastrointestinal, DFS = disease free survival, OS =
overall survival.
1Efficacy data from the current study is limited only to patients undergoing R0
resection.
2Proportion of distant relapses out of all relapses, including those combined
with locoregional relapses.
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Page 6 of 9Table 5 Comparison of different adjuvant chemoradiation studies
First author
(country, year)
Type of
study
No. of
patients
Type of
chemotherapy
T3-
4
N+ Any Gr ≥ 3
tox.
Gr > 3 Hem.
tox.
Gr > 3 Non- hem.
tox.
Toxic
deaths
Relapse
rate
Median survival
(months)
MacDonald [4]
(USA, 2001)
Phase 3 556 5FU/LV
1 66% 85% 41% 54% 63% 1% 43% 36
Park [18]
(South-Korea,2003)
Phase 2 290 5FU/LV NA 90% NA 30% 38% 0% 39% NA
Hughes [14]
(Australia, 2004)
Retrosp. 45
2 5FU/LV 85% 81% 42% 18% 20% 0% 68% 22.8
Kollmannsberger
[20]
(Germany, 2005)
Phase 2 86 DDP/5FU
PAC/DDP/5FU/LV
4
NA NA NA 81% 89% 56% 56% 0%
0%
19%
33%
NA
NA
Kim [9]
(South Korea,
2005)
Retrosp. 990 5FU/LV 48% 93% NA 30% 15% 1% 42% 95
Kassam [15]
(Canada, 2006)
Retrosp. 82
2 5FU/LV
3
DDP/5FU
53% 82% 56% 33% 34% 0% 32% NR
Lee [19]
(South-Korea,
2006)
Phase 2 31 DDP/5FU NA 100% NA 66% 12% 0% 13% NA
Oechsle [8]
(Germany,2007)
Phase 2 157 DDP/PAC/5FU/LV NA NA NA 100% 58% 0.6%
5 51% NA
DDP/5FU/LV 93% 59% 52% NA
CPT11/5FU/LV 80% 73% 100% NA
DOC/DDP/5FU 100% 30% 30% NA
Tsang13]
(Hong Kong, 2008)
Retrosp. 63
2 5FU/LV 52% 86% 30% 24% 14% 1.5% 52% NR
Hofheinz [16]
Germany, 2008)
Extend.
phase I
32
2 CAPE/OXALI 44% 97% NA 21% 42% 0% 47% NA
Di Costanzo [7]
(Italy, 2008)
Phase 3 258 DDP/EPI/5FU/LV
1 54% 84% NR 27% 75% 0.8% 48% 57
Leong [22]
(Australia, 2009)
Phase 2 54 EPI/DDP/5FU 57% 98% NA 28% 66% 0% 37% NR
Aftimos [21]
(Lebanon, 2010)
Retrosp. 24 5FU/LV
DDP/5FU
75% 71% NA 20% 36% 0% 22% 75
Chang [17]
(Hong Kong, 2011)
Retrosp. 120
2 5FU/LV 45% 93% 66% 61% 15% 0% 41% 64
Current
(Israel, 2011)
Retrosp. 166 5FU/LV 77% 85% 46% 32% 25% 1.8% 30% NR
Tox. = toxicity, Hem. = hematological, Extend. = extended, Retrosp. = retrospective, DDP = cisplatin, PAC = paclitaxel, EPI = epirubicin, CAP = capecitabine, OX = oxaliplatin, DOC = docetaxel, 5FU = 5 fluorouracil, LV
= Leucovorin. NR = not reached, NA = not available.
1The regimen used in the treatment arm. The control arm included surgery alone.
2These studies included also patients undergoing R1 resection; results of outcome represent patients undergoing R0 resection,
whenever reported separately.
3Combined analysis of more than one regimen.
4Combined report of consecutive phase II cohorts.
5Joint figure for all cohorts combined
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9[13-17]. In the absence of phase III data and conse-
quently lack of clear guidelines in this unfortunately not
uncommon situation, our results and earlier ones seem
to support the common practice of adding postoperative
chemoradiation after R1 gastrectomies.
In summary, the results of the Israeli experience seem to
confirm the substantial toxicity and the overall efficacy of
postoperative chemoradiation as given in the INT-0116
trial. The mortality rate in our routine practice seems to be
higher than in the clinical trial. Altogether, there is a clear
need for substantial improvement of the INT-0116 regi-
men, to reduce its toxicity and enhance its efficacy. In our
experience too, involvement of surgical margins is an omi-
nous prognostic sign, even after adjuvant chemoradiation.
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